Imvotamab

Cat. No.: IBDI-431956

Imvotamab (IGM-2323) is a CD20xCD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab is currently being developed for the treatment of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).

Product Details

Target	CD20 | CD3
Synonyms	IGM-2323
SMILES	[Imvotamab]

Storage & Handling

Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.